Peer-influenced content. Sources you trust. No registration required. This is HCN.

MedPage TodayNegative Trials Close the Book on Once-Promising SCLC Drug

A once-hopeful antibody-drug conjugate for small-cell lung cancer (SCLC) failed to demonstrate a survival benefit in two large, randomized studies, and was found to be mostly toxic. The negative trial results have led to the end of a drug that was considered a promising potential antidote to deadly SCLC.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form